HCS Pharma will be present at next ELRIG event “Research and Innovation 2023 – Accelerating future DD” in Cambridge on March 29 and 30th

We are pleased to participate in ELRIG event about Research an Innovation 2023 – Accelerating future drug discovery” in Cambridge on March 29 and 30th 2023. Veronique De Conto, our project leader in in vitro Pharmacology, is very happy to meet us and to present you our disruptive technology BIOMIMESYS®. Read more…

Presentation of BIOMIMESYS technology, the first organ-specific in vitro ECM, to develop innovative and predictive 3D cellular models for drug discovery – Academia Sinica, the 1st of November 2022

BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…

Poster (OncoLilleDays2022) – Mechanobiological characterization of a 3D in vitro pancreatic ductal adenocarcinoma model and the study of tumor-stroma interaction

Thomas Meynard, PhD student in OncoLille (under the supervision of Vincent Senez and Isabelle Van Seuningen) in collaboration with HCS Pharma too, presented a poster showing that it is possible to include BIOMIMESYS® in a microfluidic chip to co-culture Cancer-Associated fibroblasts and cancerous cells, with the aim to increase the Read more…

Meet us in OncoLille Days 2022 where we present a poster about matricial tumoral microenvironment in 3D in vitro models

We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…

Poster – (ECM 2022) Development of innovative hiPSC-based model including an innovative 3D modified hyaluronic acid hydroscaffold for phenotypic screening

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to studymetabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and Read more…

Using BIOMIMESYS® Oncology in cancer research, results and future possibilities

Solid tumors are associated with a modified microenvironment, in particular an enhanced collagen content and increased stiffness at the level of the extracellular matrix (ECM). These ECM changes are now recognized as important drivers of cancer initiation, progression, and propagation, and also impact the responses of cancerous cells to treatments. Read more…

[job position] Ingénieur / Ingénieure en techniques biologiques – Biotechnology Engineer (F/M)

L’ingénieur(e) d’étude mettra au point des méthodes expérimentales permettant de développer un modèle tri-dimensionelle de tumeurs colorectales et de prostate avec la technologie Biomimesys développée par HCS Pharma. La technologie de culture BIOMIMESYS® 3D reproduit fidèlement le microenvironnement naturel des cellules d’un organe cible. Il est attendu un soutien conceptuel Read more…

Extracellular Matrix Modifications in Lung Cancer Initiation, Progression and Propagation

The Extracellular Matrix (ECM) is a major component of all the organs. This dynamic structure is involved not only in cell adhesion, but also in physiological processes, including cell differentiation, migration, and maturation, tissue homeostasis, biochemical signal retention and mediation, and growth factors’ retention. Moreover, the ECM can be abnormally Read more…